Severe acute respiratory syndrome virus 2 (SARS-CoV-2), the causative agent of the ongoing pandemic of COVID-19 has already marched across 210 countries globally. This novel coronavirus is highly infectious and left us with no available cure and only with containment option. To understand the molecular epidemiology and vaccine design, genetic sequences from different regions are published and analyzed. Here, the first published whole genome sequence of Bangladesh was compared with Asian countries as well as representative strains from across the globe. Phylogenetic analysis of the first Bangladeshi genome, that was published on May 12, 2020 revealed at least 9 Single nucleotide polymorphisms from the Wuhan, China strains and 2 of these mutations are novel compared to the strains analyzed. Among the novel mutations nucleotide 1163 mutation is very novel when compared with all the genomes deposited at Global Initiative on Sharing Avian Influenza Data (GISAID). However, the other mutation at nucleotide 17019, mutation NSP13 E261D is occurred second time after a strain from Austrian patient showed the similar mutation. Structure and screening results of both novel mutation were discussed in detail. Further analysis of these identified novel mutations will boost the understanding of the behavior of SARS-CoV-2 in this region and vaccination and drug development programs would be beneficial.
SARS-CoV-2, appeared in winter 2019, in Wuhan State of Hubei Province in China, which has already marched more than 210 countries with 5,418,496 cases and 344,206 fatalities. Through an ongoing unprecedented global public health effort, the pandemic is now slowing down slightly after 6 months of its original occurrence. Until now, the media coverage is incredibly accurate and has been providing worldwide pictures to enrich scientific data. As of May 25, 2019, there are more than 21000 citations related to SARS-CoV-2 in the medical literature according to the WHO on global research on coronavirus disease 2019 (COVID-19). However, among these citations, only 5-10% are related to laboratory experimental data. This review is aimed to analyze the unique laboratory experiment aspects of SARS-CoV-2, to describe the epidemiology, threat to pediatric and women health, mutational intimidation, diagnostics and treatment of the SARS-CoV-2 in regard to future epidemics, and to use the SARS-CoV-2 experience as a model for future pandemics.